Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29617443
Publication Date : //

Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C.


Sustained virological response (SVR) rates have increased remarkably since the introduction of direct-acting antiviral agents (DAAs) for chronic hepatitis C. Autotaxin (ATX) is a secreted enzyme converting lysophosphatidylcholine to lysophosphatidic acid and a newly established biomarker for liver fibrosis. Interferon-free DAA regimens for chronic hepatitis C could improve liver stiffness in SVR patients according to several non-invasive evaluation methods, but the clinical response and significance of ATX in this context have not yet been defined. We therefore investigated sequential serum ATX levels at baseline, 4 weeks after the start of treatment, and 24 weeks after treatment in 159 hepatitis C virus (HCV)-infected patients who received DAA therapy. Other non-invasive fibrosis markers (aspartate aminotransferase-to-platelet ratio and FIB-4 index) were examined as well. Baseline median ATX levels were comparable between the 144 patients who achieved a SVR and the 15 who did not (1.54 vs. 1.62 mg/L), but median ATX levels became significantly decreased during and after DAA therapy in the SVR group only (from 1.54 to 1.40 and 1.31 mg/L, respectively; P < 0.001). ATX was significantly decreased between baseline and 4 weeks of treatment in overall, male, and female SVR patients (all P < 0.001). In subjects with low necroinflammatory activity in the liver (i.e., alanine aminotransferase < 30 U/L), ATX levels were significantly reduced from baseline to 4 weeks of treatment and remained low (P < 0.001) in patients with a SVR. Thus, interferon-free DAA therapy was associated with a significant decrease in serum ATX levels in patients achieving a SVR, suggesting early regression of liver fibrosis in addition to inflammation treatment.

Authors : Yamazaki Tomoo , Joshita Satoru , Umemura Takeji , Usami Yoko , Sugiura Ayumi , Fujimori Naoyuki , Kimura Takefumi , Matsumoto Akihiro , Igarashi Koji , Ota Masao , Tanaka Eiji ,

Related products :

Catalog number Product name Quantity
31-076 DOK2 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210 (bcr 0.05 mg
31-062 DOK1 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210 (bcr 0.05 mg
B437 Brain Heart Infusion w_PABA USE For examination of blood from patients under sulphonamide therapy. Qty per Litre of Medium: 37
B437 Brain Heart Infusion w_PABA USE : For examination of blood from patients under sulphonamide therapy. 5x500gm
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
orb61239 Dasatinib Dasatinib is an oral multi- BCR_ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia ch 100 mg
303-08741 tic and noncataractous), renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, diabetic retina, peripheral nerves of diabetic neuropathy, atherosclerotic lesions of a 20UG
orb60938 Clonidine hydrochloride Clonidine hydrochloride(Catapres) is a direct-acting alpha 2 adrenergic agonist with an ED50 of 0.02 +_-0.01 mg_kg. For research use only. 10 mg
27-963 ARHGDIG is highly expressed in the entire brain, with regional variations. The mRNA is also present at high levels in kidney and pancreas and at moderate levels in spinal cord, stomach, and pituitary 0.05 mg
orb60582 Telbivudine Telbivudine(Tyzeka, Sebivo) is an antiviral drug used in the treatment of hepatitis B infection. For research use only. 10 mg
CSLKITCU CellasKIT IFE SERUM + CONCENTRATED URINE (5+5 tests for 5 patients) on CellasGEL 1
DOAIF-123-E Human Serum (OsteoArthritis Patients) Female Individual Donor 5ml
CSLKITCU CellasKIT IFE SERUM + CONCENTRATED URINE (5+5 tests for 5 patients) on CellasGEL
DOAIF-123-E Human Serum (OsteoArthritis Patients) Female, Individual donors unit
DOAIF-123-E Human Serum (OsteoArthritis Patients) Female, Individual donors 5 ml
RELSKITCU CellasKIT IFE SERUM + CONCENTRATED URINE (5+5 tests for 5 patients) on CellasGEL
EIAAB46919 Rat,Rattus norvegicus,rZAP,ZAP,Zap,Zc3hav1,Zinc finger antiviral protein,Zinc finger CCCH-type antiviral protein 1
CSB-EL013526RA Rat mitochondrial antiviral signaling protein (MAVS) ELISA kit, Species Rat, Sample Type serum, plasma 96T
VAC-HBS-50 VacciGel Direct ELISA for the measurement of Hepatitis B Vaccine (HBsAg) formulated in Alum, 96 tests 1 kit
CSB-EL026369RA Rat zinc finger CCCH-type, antiviral 1 (ZC3HAV1) ELISA kit, Species Rat, Sample Type serum, plasma 96T
CSB-EL013526MO Mouse mitochondrial antiviral signaling protein (MAVS) ELISA kit, Species Mouse, Sample Type serum, plasma 96T
CSB-EL013526HU Human mitochondrial antiviral signaling protein (MAVS) ELISA kit, Species Human, Sample Type serum, plasma 96T
PCR-111S Direct PCR Kit, S pack Kit for direct PCR amplification from blood, animal and plant tissue 2,5ml
PCR-111L Direct PCR Kit, L pack Kit for direct PCR amplification from blood, animal and plant tissue 12,5ml
K3004-1 Retinol Binding Protein EIA Kit The RBP Immunoassay Kit is designed to measure RBP levels in serum and EDTA and heparin plasmas. This kit uses a native human RBP molecule as a standard, the concentrat 96 rxns


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur